NASDAQ:OPT - Opthea Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $36.00
  • Forecasted Upside: 188.46 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$12.48
▲ +0.63 (5.32%)
1 month | 3 months | 12 months
Get New Opthea Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OPT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OPT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$36.00
▲ +188.46% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Opthea in the last 3 months. The average price target is $36.00, with a high forecast of $48.00 and a low forecast of $25.00. The average price target represents a 188.46% upside from the last price of $12.48.
Buy
The current consensus among 6 polled investment analysts is to buy stock in Opthea.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/30/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/21/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/18/2020CIBCReiterated RatingHold$26.00Medium
i
11/17/2020Smith Barney CitigroupInitiated CoverageBuy$48.00Low
i
11/17/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellInitiated CoverageBuy$48.00High
i
11/11/2020SVB LeerinkInitiated CoverageOutperform$33.00High
i
Rating by G. Porges at SVB Leerink LLC
11/11/2020OppenheimerInitiated CoverageOutperform$36.00High
i
11/11/2020TruistInitiated CoverageBuy$25.00High
i
(Data available from 1/20/2016 forward)
Opthea logo
Opthea Limited, a biotechnology company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3 for the treatment of wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
Read More

Today's Range

Now: $12.48
$11.95
$12.56

50 Day Range

MA: $12.00
$11.11
$13.21

52 Week Range

Now: $12.48
$10.22
$17.86

Volume

2,049 shs

Average Volume

7,152 shs

Market Capitalization

$526.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Opthea?

The following equities research analysts have issued research reports on Opthea in the last twelve months: CIBC, Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Oppenheimer Holdings Inc., Smith Barney Citigroup, SVB Leerink LLC, and Truist.

What is the current price target for Opthea?

6 Wall Street analysts have set twelve-month price targets for Opthea in the last year. Their average twelve-month price target is $36.00, suggesting a possible upside of 188.2%. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell has the highest price target set, predicting OPT will reach $48.00 in the next twelve months. Truist has the lowest price target set, forecasting a price of $25.00 for Opthea in the next year.

What is the current consensus analyst rating for Opthea?

Opthea currently has 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OPT will outperform the market and that investors should add to their positions of Opthea.

What other companies compete with Opthea?

How do I contact Opthea's investor relations team?

Opthea's physical mailing address is LEVEL 4 650 CHAPEL STREET, SOUTH YARRA VICTORIA C3, 3141. The company's listed phone number is 61 3 9826 0399. The official website for Opthea is www.opthea.com.